None of these are deal-breakers on their own, but they add up
These medications mimic the activity of natural hormone glucagon-like peptide-1 (GLP-1) receptors located in the pancreas, brain, and gut to slow gastric emptying, increase insulin secretion, reduce appetite, and improve blood glucose levels
2019 ESC guidelines on dia- betes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes
Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action
likewise, compensatory hyperinsulinemia in the setting of insulin resistance could also contribute to anomalies in vaso-reactivity, angiogenesis, and fibrosis implicated in CKD and atherogenesis [53]